Short answer
Organogenesis Holdings Inc. (ORGO) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $37M (down 57.1% year over year) with net income of −$53M.
Q1 2026 key financials · XBRL
- Revenue
- $37M
- −57.1% YoY
- Net income
- −$53M
- −182.1% YoY
- Operating margin
- -185.1%
- EPS (diluted)
- −$0.44
- −158.8% YoY
Source: XBRL data from the Organogenesis Holdings Inc. (ORGO) Q1 2026 10-Q on SEC EDGAR. USD.
Organogenesis Holdings Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 revenue $37.2M vs $86.7M, down $49.5M YoY
- Gross margin 28.1% vs 72.6% YoY; net loss $53.2M vs $18.8M
- Advanced Wound Care $29.5M, down 63%; Surgical & Sports Medicine $6.8M, flat YoY
- Cash $91.4M; operating cash flow $21.1M vs $(19.9)M; capital expenditures $3.1M
- CMS reimbursement changes and discarded-product comments driving significant revenue declines; outlook uncertain
Risk Factors
- Newly added executive-retention risk triggered by May 6, 2026 Key Employee Agreements
- Change-in-control exposure: severance up to 2x salary and target bonus for CEO
- Executive departure costs: severance and COBRA payments following qualifying termination
- Talent-retention risk: agreements require new noncompetition agreements and claims releases
- No financial, operational, competitive, or regulatory risks disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Organogenesis Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.